CLAIMS

We claim:

1. A compound of selected from a compound of Formula (II), Formula (III), Formula (IV), Formula (V), or Formula (VI):



Formula (II)

,



Formula (III)

,



Formula (IV)



Formula (V)

, or



Formula (VI)

wherein:

A^2 is independently N, NR^{2a}, CR^{2b}, or –C(=O)–;

A^3 is independently CR^3 or N;

A^4 is CR^8 or N;

A^5 and A^6 are each independently CR^8 or N, or A^5 and A^6 taken together are O, NR^9, or S;

W^1, W^2, W^3, and W^4 are each independently N or CR^4, or W^1 and W^2 taken together is O, NR^{4A}, or S, or W^2 and W^3 taken together is O, NR^{4A}, or S;

Y is a bond or a linker having a length of up to 6 atoms;

Z^1, Z^2, Z^3, and Z^4 are each independently N or CR^5, or Z^2 and Z^3 taken together is O, NR^{5A}, or S, or Z^3 and Z^4 taken together is O, NR^{5A}, or S;

R^{1a} and R^{2a} are each independently R^9, $–OR^9$, $–C(O)R^9$, $–C(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–S(O)_pR^9$, or $–S(O)_2NR^{10}R^{11}$;

R^{1b}, R^{2b}, R^3, R^5 and R^8, at each occurrence, are each independently R^9, $–OR^9$, halo, CN, NO_2, $–C(O)R^9$, $–C(O)OR^9$, $–OC(O)R^9$, $–OC(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^9$, $–NR^{10}C(O)OR^9$, $–NR^{10}C(O)NR^{10}R^{11}$, $–NR^{10}S(O)_2R^9$, $–S(O)_pR^9$, $–S(O)_2NR^{10}R^{11}$ or $–NR^{10}S(O)_2NR^{10}R^{11}$;

R^4, at each occurrence, is independently hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} hydroxyalkoxy, C_{1-6} heteroalkoxy, C_{3-6} cycloalkoxy, 3-6 membered heterocycloalkoxy, $–NR^{14}R^{15}$, C_{6-12} aryl, or 5-12 membered heteroaryl, wherein each C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} hydroxyalkoxy, C_{1-6} heteroalkoxy, C_{3-6} cycloalkoxy, 3-6 membered heterocycloalkoxy, C_{6-12} aryl, or 5-12 membered heteroaryl of the R^4 is optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, and (O);

R^{4A} and R^{5A} are independently hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{6-12} aryl, or 5-12 membered heteroaryl, wherein each C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{6-12} aryl, or 5-12 membered heteroaryl of the R^{4A} and the R^{5A} are optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6}

heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, and (O);

R^6 is CN, R^9, $–OR^9$, $–C(O)R^9$, $–C(O)OR^9$, $–OC(O)R^9$, $–OC(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}OR^9$, $–NR^{10}C(O)R^9$, $–NR^{10}C(O)OR^9$, $–NR^{10}C(O)NR^{10}R^{11}$, $–NR^{10}S(O)_2R^9$, $–NR^{10}C(NR^{10})NR^{10}R^{11}$, $–S(O)_pR^9$, $–S(O)_2NR^{10}R^{11}$, or $–NR^{10}S(O)_2NR^{10}R^{11}$;

R^7 is a 5-12 membered heteroaryl, optionally substituted with 1-4 substituents independently selected from halo, CN, NO_2, R^9, $–OR^9$, $–C(O)R^9$, $–C(O)OR^9$, $–OC(O)R^9$, $–OC(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^9$, $–NR^{10}C(O)OR^9$, $–NR^{10}C(O)NR^{10}R^{11}$, $–NR^{10}S(O)_2R^9$, $–S(O)_pR^9$, $–S(O)_2NR^{10}R^{11}$ and $–NR^{10}S(O)_2NR^{10}R^{11}$;

R^9, at each occurrence, is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{6-12} aryl, or 5-12 membered heteroaryl, wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{6-12} aryl, or 5-12 membered heteroaryl of the R^9 is optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, CN, NO_2, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, (O), $–C(O)R^{12}$, $–C(O)OR^{12}$, $–OC(O)R^{12}$, $–OC(O)OR^{12}$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^{12}$, $–NR^{10}C(O)OR^{12}$, $–NR^{10}C(O)NR^{10}R^{11}$, $–NR^{10}S(O)_2R^{12}$, $–S(O)_pR^{12}$, $–S(O)_2NR^{10}R^{11}$, and $–NR^{10}S(O)_2NR^{10}R^{11}$;

R^{10} and R^{11}, at each occurrence, are each independently hydrogen, hydroxy, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{6-12} aryl, or 5-12 membered heteroaryl, or together with the N to which each is attached are combined to form a 3-6 membered heterocycloalkyl, wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{6-12} aryl, or 5-12 membered heteroaryl of the R^{10} and the R^{11} is optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, CN, NO_2, C_{1-6} alkyl, C_{2-6}

alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, (O), $–C(O)R^{13}$, $–C(O)OR^{13}$, $–OC(O)R^{13}$, $–OC(O)OR^{13}$, $–C(O)NR^{14}R^{15}$, $–NR^{14}R^{15}$, $–NR^{14}C(O)R^{13}$, $–NR^{14}C(O)OR^{13}$, $–NR^{14}C(O)NR^{14}R^{15}$, $–NR^{14}S(O)_2R^{13}$, $–S(O)_pR^{13}$, $–S(O)_2NR^{14}R^{15}$, and $–NR^{14}S(O)_2NR^{14}R^{15}$;

R^{12}, at each occurrence, is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{6-12} aryl, or 5-12 membered heteroaryl, wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{6-12} aryl, or 5-12 membered heteroaryl of the R^{12} is optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, CN, NO_2, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, (O), $–C(O)R^{13}$, $–C(O)OR^{13}$, $–OC(O)R^{13}$, $–OC(O)OR^{13}$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^{13}$, $–NR^{10}C(O)OR^{13}$, $–NR^{10}C(O)NR^{10}R^{11}$, $–NR^{10}S(O)_2R^{13}$, $–S(O)_pR^{13}$, $–S(O)_2NR^{10}R^{11}$, and $–NR^{10}S(O)_2NR^{10}R^{11}$;

R^{13}, at each occurrence, is independently hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} heteroalkyl, C_{3-6} cycloalkyl, or 3-6 membered heterocycloalkyl;

R^{14} and R^{15}, at each occurrence, are each independently hydrogen, hydroxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, or C_{1-6} alkoxy, or together with the N to which each is attached are combined to form a 3-6 membered heterocycloalkyl; and

each p is independently an integer of 0, 1 or 2.

or a pharmaceutically acceptable form thereof.

2. The compound of claim 1, wherein the compound is a compound of Formula (II), or a pharmaceutically acceptable form thereof.

3. The compound of claim 1, wherein the compound is a compound of Formula (III), or a pharmaceutically acceptable form thereof.

4. The compound of claim 3, wherein the compound is a compound of Formula (IIIa) or is a compound of Formula (IIIb):



Formula (IIIa)



Formula (IIIb)

or a pharmaceutically acceptable form thereof.

5. The compound of claim 3, wherein the compound is a compound of Formula (III-1), (IIIa-1), (IIIb-1), (III-2), (IIIa-2), (IIIb-2), (III-3), (IIIa-3), or (IIIb-3):



Formula (III-1)



Formula (IIIa-1)



Formula (IIIb-1)



Formula (III-2)



Formula (IIIa-2)



Formula (IIIb-2)



Formula (III-3)



Formula (IIIa-3)



Formula (IIIb-3)

or a pharmaceutically acceptable form thereof.

6. The compound of claim 1, wherein the compound is a compound of Formula (IV), or a pharmaceutically acceptable form thereof.

7. The compound of claim 1, wherein the compound is a compound of Formula (V), or a pharmaceutically acceptable form thereof.

8. The compound of claim 1, wherein the compound is a compound of Formula (VI), or a pharmaceutically acceptable form thereof.

9. The compound of claim 1, wherein R^{2b} is R^9, $–OR^9$, halo, CN, NO_2, $–C(O)R^9$, $–C(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^9$, $–S(O)_pR^9$, or $–S(O)_2NR^{10}R^{11}$.

10. The compound of claim 1, wherein:

(a) A^3 is CR^3, optionally wherein R^3 is (a) independently R^9, $–OR^9$, halo, or CN; or (b) hydrogen;

(b) A^4 is CR^8;

(c) A^5 is CR^8;

(d) A^6 is CR^8; or

(e) a combination of one or more of (a)-(d).

11. The compound of any one of claims 1-10, wherein R^8 is independently R^9, $–OR^9$, halo, or CN, optionally wherein R^8 is hydrogen.

12. The compound of any one of claims 1-11, wherein Y is in the direction of Z-Y-W, and wherein Y is a C_{1-6} alkylene, wherein one or more $–CH_2–$ is optionally independently replaced by –O–, –C(O)–, $–N(R^{10})–$, $–N(R^{10})C(O)–$, $–C(O)N(R^{10})–$, $–N(R^{10})C(O)N(R^{11})–$, $–S(O)_p–$, $–N(R^{10})S(O)_2–$, $–S(O)_2N(R^{10})–$, or $–N(R^{10})S(O)_2N(R^{11})–$; and wherein Y is no more than six atoms in length.

13. The compound of any one of claims 1-12, wherein:

Y is $–(CR^{16}R^{17})_q–$, $–(CR^{16}R^{17})_mO(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mC(O)(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mN(R^{10})(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mN(R^{10})C(O)(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mC(O)N(R^{10})(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mN(R^{10})C(O)N(R^{11})(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mS(O)_p(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mN(R^{10})S(O)_2(CR^{16}R^{17})_n–$, $–(CR^{16}R^{17})_mS(O)_2N(R^{10})(CR^{16}R^{17})_n–$, or $–(CR^{16}R^{17})_mN(R^{10})S(O)_2N(R^{11})(CR^{16}R^{17})_n–$;and wherein Y is no more than six atoms in length; and

wherein:

R^{16} and R^{17}, at each occurrence, are each independently hydrogen, halo, hydroxy, CN, NO_2, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} hydroxyalkoxy, C_{1-6} heteroalkoxy, or 3-6 membered heterocycloalkoxy, or together with the C to which each is attached are combined to form a C(O), C_{3-6} cycloalkyl, or 3-6 membered heterocycloalkyl;

each m is independently an integer of 0, 1, 2 or 3;

each n is independently an integer of 0, 1, 2 or 3;

wherein the sum of m and n is 0, 1, 2, 3, 4, 5, or 6;

each p is independently an integer of 0, 1 or 2; and

each q is independently an integer of 0, 1, 2, 3, 4, 5, or 6;

optionally wherein m is 0, 1, or 2; and

optionally wherein n is 0, 1, or 2.

14. The compound of any one of claims 1-13, wherein Y is $–(CH_2)O–$, or Y is $–O(CH_2)–$, or Y is $–(CH_2)_2O–$, or Y is $–O(CH_2)_2–$, or Y is $–(CH_2)_2–$.

15. The compound of any one of claims 1-14, wherein:

(a) R^4 is independently hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} hydroxyalkoxy, C_{1-6} heteroalkoxy, C_{3-6} cycloalkoxy, 3-6 membered heterocycloalkoxy, or $–NR^{14}R^{15}$, wherein each C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} hydroxyalkoxy, C_{1-6} heteroalkoxy, C_{3-6} cycloalkoxy, or 3-6 membered heterocycloalkoxy, of the R^4 are optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6}

heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, and (O); or

(b) R^4 is independently hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, or C_{1-6} haloalkoxy, wherein each C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, or C_{1-6} haloalkoxy of the R^4 are optionally independently substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, and (O); or

(c) R^4 is independently hydrogen, halo, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-5} cycloalkyl, C_{1-3} alkoxy, or C_{1-3} haloalkoxy; or

(d) each R^4 is independently hydrogen.

16. The compound of any one of claims 1-15, wherein R^5, at each occurrence, is independently R^9, $–OR^9$, halo, CN, NO_2, $–C(O)R^9$, $–C(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–S(O)_pR^9$, or $–S(O)_2NR^{10}R^{11}$; or R^5, at each occurrence, is independently hydrogen, halo, CN, NO_2, $–C(O)CH_3$, –C(O)OH, $–C(O)OCH_3$, $–C(O)N(CH_3)_2$, $–S(O)_2CH_3$, or $–S(O)_2N(CH_3)_2$; or each R^5 independently is hydrogen, halo or CN; or each R^5 independently is hydrogen.

17. The compound of any one of claims 1-16, wherein R^7 is an imidazolyl, a triazolyl, a tetrazolyl, an oxazolyl, a thiazolyl, an oxadiazolyl, a thiadiazolyl, a pyridyl, or a pyrimidinyl, optionally substituted with 1-4 substituents independently selected from halo, CN, NO_2, R^9, $–OR^9$, $–C(O)R^9$, $–C(O)OR^9$, $–OC(O)R^9$, $–OC(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^9$, $–NR^{10}C(O)OR^9$, $–NR^{10}C(O)NR^{10}R^{11}$, $–NR^{10}S(O)_2R^9$, $–S(O)_pR^9$, $–S(O)_2NR^{10}R^{11}$, or $–NR^{10}S(O)_2NR^{10}R^{11}$;

optionally R^7 is imidazolyl or triazolyl, optionally substituted with 1-4 substituents independently selected from halo, CN, NO_2, R^9, $–OR^9$, $–C(O)R^9$, $–C(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^9$, $–S(O)_pR^9$, or $–S(O)_2NR^{10}R^{11}$;

optionally R^7 is a *C*-linked imidazolyl or a *C*-linked triazolyl, optionally substituted with 1-4 substituents independently selected from halo, CN, NO_2, R^9, $–OR^9$, $–C(O)R^9$, $–C(O)OR^9$, $–C(O)NR^{10}R^{11}$, $–NR^{10}R^{11}$, $–NR^{10}C(O)R^9$, $–S(O)_pR^9$, or $–S(O)_2NR^{10}R^{11}$.

18. The compound of any one of claims 1-17, wherein R^6 is CN, R^9, $–OR^9$, $–OC(O)R^9$, $–OC(O)OR^9$, $–NR^{10}R^{11}$, $–NR^{10}OR^9$, $–NR^{10}C(O)R^9$, or $–NR^{10}C(NR^{10})NR^{10}R^{11}$, or wherein R^6 is CN, R^9, $–OR^9$, $–NR^{10}R^{11}$, or $–NR^{10}OR^9$, or wherein R^6 is CN, R^9, $–OR^9$, or $–NR^{10}R^{11}$, optionally wherein R^9 is independently hydrogen or C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with CN, and optionally wherein R^{10} and R^{11} are each independently hydrogen, C_{1-6} alkyl or C_{1-6} alkoxy.

19. The compound of any one of claims 1-18, wherein:
the compound has a MW of no more than 1,000 g/mol; or
the compound has a MW of no more than 900 g/mol, no more than 800 g/mol, no more than 700 g/mol, no more than 600 g/mol, or no more than 500 g/mol; or
the compound has a MW of no more than 600 g/mol; or
the compound has a MW of no more than 500 g/mol.

20. The compound of claim 1, wherein the compound is selected from Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, and 135, including (R)- or (S)-stereoisomers. Racemates, and diastereomers thereof, or a pharmaceutically acceptable form thereof.

21. The compound of any one of claims 1-20, wherein the compound is a racemate, a mixture of diastereomers, or a mixture of stereoisomers, or a pharmaceutically acceptable form thereof.

22. The compound of any one of claims 1-20, wherein the compound is a single enantiomer or a single diastereomer, or a pharmaceutically acceptable form thereof; optionally wherein the compound is a single enantiomer with an (*R*)-configuration at the R^6/R^7-substituted carbon, or a pharmaceutically acceptable form thereof; or optionally wherein the compound is a single enantiomer with an (*S*)-configuration at the R^6/R^7-substituted carbon, or a pharmaceutically acceptable form thereof.

23. The compound of any one of claims 1-22, wherein the pharmaceutically acceptable form of the compound is exclusive of a salt form.

24. A pharmaceutical composition comprising the compound or pharmaceutically acceptable form thereof, of any one of claims 1-23, and a pharmaceutically acceptable carrier, excipient or diluent.

25. Use of the compound or pharmaceutically acceptable form thereof, of any one of claims 1-23, or of the pharmaceutical composition of claim 24, in the manufacture of a medicament for inhibiting a farnesyltransferase, wherein the use comprises contacting the farnesyltransferase with an effective amount of the compound or pharmaceutically acceptable form thereof, or with the pharmaceutical composition,
optionally wherein the farnesyltransferase is present in a cell,
optionally wherein the contacting of the farnesyltransferase takes place in a cell, optionally wherein the cell is in a subject, optionally wherein the cell is a mammalian cell, optionally wherein the cell is a human cell, and
optionally wherein the subject suffers from a cancer dependent on a farnesylated protein.

26. Use of the compound or pharmaceutically acceptable form thereof, of any one of claims 1-23, or of the pharmaceutical composition of claim 24, in the manufacture of a medicament for treating cancer dependent on a farnesylated protein in a subject, wherein the use comprises administering a therapeutically effective amount of the compound or pharmaceutically acceptable form thereof, or the pharmaceutical composition, to the subject having cancer dependent on a farnesylated protein, optionally wherein the subject is human.

27. The use of claim 25 or claim 26, wherein the cancer dependent on a farnesylated protein is a cancer dependent on farnesylated H-Ras protein, optionally wherein the cancer dependent on a farnesylated protein has an H-Ras protein mutation, optionally wherein the H-Ras protein mutation is or comprises a modification in a codon that encodes an amino acid substitution at a specific position selected from G12, G13, Q61, Q22, K117, A146, and any combination thereof, in the corresponding mutant H-Ras protein;

optionally wherein the presence or absence of the H-Ras mutation has been determined by analysis of nucleic acids obtained from a sample from the subject, optionally wherein the sample is a tissue biopsy or is a tumor biopsy, optionally wherein the H-Ras mutation has been determined by sequencing, Polymerase Chain Reaction (PCR), DNA microarray, Mass Spectrometry (MS), Single Nucleotide Polymorphism (SNP) assay, denaturing high-performance liquid chromatography (DHPLC), or Restriction Fragment Length Polymorphism (RFLP) assay.

28. The use of any one of claims 25-27, wherein the cancer dependent on a farnesylated protein is a cancer dependent on farnesylated N-Ras protein, optionally wherein the cancer dependent on a farnesylated protein has an N-Ras protein mutation, optionally wherein the N-Ras mutation is or comprises a modification in a codon that encodes an amino acid substitution at a specific position selected from G12, G13, Q61, Q22, K117, A146, and any combination thereof, in the corresponding mutant N-Ras protein;

optionally wherein determining the presence or absence of the N-Ras mutation comprises analyzing nucleic acids obtained from a sample from the subject, optionally wherein the N-Ras

mutation is determined by sequencing, Polymerase Chain Reaction (PCR), DNA microarray, Mass Spectrometry (MS), Single Nucleotide Polymorphism (SNP) assay, denaturing high-performance liquid chromatography (DHPLC), or Restriction Fragment Length Polymorphism (RFLP) assay, optionally wherein the sample is a tissue biopsy or a tumor biopsy.

29. The use of any one of claims 25-28, wherein the cancer dependent on a farnesylated protein is:

(a) melanoma, acute myeloid leukemia (AML), thyroid carcinoma, lung adenocarcinoma, rectal carcinoma, endometrial carcinoma, or colorectal carcinoma;

(b) carcinoma, melanoma, sarcoma, or chronic granulomatous disease;

(c) thyroid cancer, head and neck cancers, urothelial cancers, salivary cancers, cancers of the upper digestive tract, bladder cancer, breast cancer, ovarian cancer, brain cancer, gastric cancer, prostate cancer, lung cancer, colon cancer, skin cancer, liver cancer, or pancreatic cancer;

(d) head and neck cancer, optionally wherein the head and neck cancer is head and neck squamous cell carcinoma (HNSCC);

(e) Squamous Cell Carcinoma (SCC), optionally wherein the SCC is head and neck SCC (HNSCC), lung SCC (LSCC), thyroid SCC (TSCC), esophagus SCC (ESCC), bladder SCC (BSCC) or urothelial carcinoma (UC), optionally wherein the SCC is HNSCC, optionally wherein the HNSCC is HNSCC of the trachea, HNSCC of the maxilla, HNSCC of the oral cavity; or

(f) a solid tumor.